Trial Profile
Newer Direct-Acting Anti-Viral Agents as Sole Therapy of Porphyria Cutanea Tarda in Subjects With Chronic Hepatitis C
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C; Porphyria cutanea tarda
- Focus Therapeutic Use
- 22 Feb 2023 Results (n=15; Between September 2017 and May 2020) assessing efficacy of ledipasvir/sofosbuvir for the treatment of porphyria cutanea tarda with chronic hepatitis C, published in the Digestive Diseases and Sciences.
- 03 Aug 2022 Status changed from active, no longer recruiting to completed.
- 01 Jun 2022 Planned End Date changed from 30 May 2022 to 1 Sep 2022.